{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:08:59Z","timestamp":1779228539307,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-026-00296-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:02:27Z","timestamp":1779228147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved \u03b2-cell function: a case report suggesting acquired incretin resistance"],"prefix":"10.1186","volume":"12","author":[{"given":"Sai","family":"Prasad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarushi","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Nagda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaily","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhi","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Vardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"296_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: International Diabetes Federation; 2021."},{"issue":"Suppl 1","key":"296_CR2","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S158\u201378.","journal-title":"Diabetes Care"},{"issue":"11","key":"296_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"296_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"296_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst JJ, Vilsb\u00f8ll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1\u20132):127\u201336.","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"296_CR6","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"296_CR7","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.2337\/dc06-0706","volume":"29","author":"B Charbonnel","year":"2006","unstructured":"Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638\u201343.","journal-title":"Diabetes Care"},{"issue":"4","key":"296_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W","volume":"15","author":"DR Matthews","year":"1998","unstructured":"Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med. 1998;15(4):297\u2013303.","journal-title":"Diabet Med"},{"issue":"21","key":"296_CR9","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005\u201312.","journal-title":"JAMA"},{"issue":"6","key":"296_CR10","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","volume":"181","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211\u201334.","journal-title":"Eur J Endocrinol"},{"issue":"18","key":"296_CR11","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1073\/pnas.0710402105","volume":"105","author":"N Sonoda","year":"2008","unstructured":"Sonoda N, Imamura T, Yoshizaki T, et al. \u03b2-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic \u03b2 cells. Proc Natl Acad Sci USA. 2008;105(18):6614\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"296_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.mce.2013.11.010","volume":"382","author":"SN Roed","year":"2014","unstructured":"Roed SN, Wismann P, Underwood CR, et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol. 2014;382(2):938\u201349.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"296_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s004240050558","volume":"435","author":"J Gromada","year":"1998","unstructured":"Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch. 1998;435(5):583\u201394.","journal-title":"Pflugers Arch"},{"issue":"8","key":"296_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","volume":"14","author":"CF Deacon","year":"2012","unstructured":"Deacon CF, Mannucci E, Ahr\u00e9n B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes\u2014a review and meta analysis. Diabetes Obes Metab. 2012;14(8):762\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"296_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696\u2013708.","journal-title":"Diabetologia"},{"issue":"4","key":"296_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2337\/dc09-1867","volume":"33","author":"B Ahr\u00e9n","year":"2010","unstructured":"Ahr\u00e9n B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730\u20135.","journal-title":"Diabetes Care"},{"issue":"23","key":"296_CR17","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427\u201343.","journal-title":"N Engl J Med"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"296_CR19","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","volume":"9","author":"B Jones","year":"2018","unstructured":"Jones B, Buenaventura T, Kanda N, et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat Commun. 2018;9(1):1602.","journal-title":"Nat Commun"},{"issue":"2","key":"296_CR20","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1152\/ajpendo.00551.2012","volume":"305","author":"RS Kuna","year":"2013","unstructured":"Kuna RS, Girada SB, Asalla S, et al. Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic \u03b2-cells. Am J Physiol Endocrinol Metab. 2013;305(2):E161\u201370.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"296_CR21","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1210\/me.2006-0178","volume":"20","author":"CA Syme","year":"2006","unstructured":"Syme CA, Zhang L, Bisello A. Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor. Mol Endocrinol. 2006;20(12):3400\u201311.","journal-title":"Mol Endocrinol"},{"issue":"8","key":"296_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1210\/mend.11.8.9959","volume":"11","author":"C Widmann","year":"1997","unstructured":"Widmann C, Dolci W, Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol. 1997;11(8):1094\u2013102.","journal-title":"Mol Endocrinol"},{"issue":"12","key":"296_CR23","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","volume":"48","author":"G Xu","year":"1999","unstructured":"Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both \u03b2-cell replication and neogenesis, resulting in increased \u03b2-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270\u20136.","journal-title":"Diabetes"},{"issue":"3","key":"296_CR24","first-page":"952","volume":"80","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"296_CR26","doi-asserted-by":"publisher","first-page":"e005442","DOI":"10.1136\/bmjopen-2014-005442","volume":"4","author":"K Esposito","year":"2014","unstructured":"Esposito K, Chiodini P, Maiorino MI, et al. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open. 2014;4(6):e005442.","journal-title":"BMJ Open"},{"issue":"4","key":"296_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/07853890.2016.1157263","volume":"48","author":"J Mamza","year":"2016","unstructured":"Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med. 2016;48(4):224\u201334.","journal-title":"Ann Med"},{"issue":"11","key":"296_CR28","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080\u20136.","journal-title":"Diabetes Care"},{"issue":"9403","key":"296_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"issue":"5","key":"296_CR30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4103\/ijem.IJEM_206_17","volume":"21","author":"AG Unnikrishnan","year":"2017","unstructured":"Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genotype and phenotype based approach to therapy in type 2 diabetes in India. Indian J Endocrinol Metab. 2017;21(5):684\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"296_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"296_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2337\/db09-1899","volume":"59","author":"JJ Meier","year":"2010","unstructured":"Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired \u03b2-cell function? Diabetes. 2010;59(5):1117\u201325.","journal-title":"Diabetes"},{"issue":"3","key":"296_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","volume":"50","author":"T Vilsb\u00f8ll","year":"2001","unstructured":"Vilsb\u00f8ll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609\u201313.","journal-title":"Diabetes"},{"issue":"11","key":"296_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00296-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:02:32Z","timestamp":1779228152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00296-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00296-2","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the Declaration of Helsinki. Ethical approval for this case report was waived by the Institutional Ethics Committee. Written informed consent was obtained from the patient for participation in this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying data. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}